Vaxcyte Shares Soar on Positive Phase 3 Vaccine Data ($PCVX)
Vaxcyte's pneumonia vaccine VAX-31 just hit all its goals in a major trial, matching or beating today's top shots from Pfizer and Merck. Shares spiked as much as 57% premarket, still up ~39% by the open. FDA filing targeted for 2028. $PCVX
Why it matters A clean head-to-head win against the market-leading pneumococcal vaccines positions this clinical-stage biotech to challenge Pfizer and Merck in a multi-billion-dollar vaccine market.
What we verified We cross-checked Vaxcyte's Oct 5, 2026 OPUS-1 Phase 3 topline results (all co-primary noninferiority/superiority endpoints met versus PCV20 and PCV21, 20 of 20 serotypes versus PCV20 and 17 of 19 versus PCV21 meeting noninferiority, and a safety profile comparable to existing vaccines) and the stock's sharp rise (as much as +57% premarket to a 52-week high, still +39% by the open to $78.33 from a $56.48 prior close) via Vaxcyte's official press release and independent reporting from RTTNews and Benzinga.
For information only. Not financial advice. See our disclaimer and editorial standards . Spotted an error? Tell us .
